Ovarian low malignant potential tumour
Not recruitingStudy of catequentinib (AL3818) combined with platinum chemotherapy for patients with recurrent or metastatic ovarian, fallopian tube, or primary peritoneal cancer
Study of catequentinib (AL3818) combined with platinum chemotherapy for patients with recurrent or metastatic ovarian, fallopian tube, or primary peritoneal cancer
- Disease:Ovarian low malignant potential tumour
- Substances:Catequentinib Dihydrochloride
Italy- Participants:18–64 years · 65+ years
- Substances:Catequentinib Dihydrochloride
- Sponsor:Advenchen Laboratories LLC



